REPL
Replimune Group, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+37/100
Last price
13.10
▼ 0.05 (0.38%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.03
Prev close
13.15
Day high
13.51
Day low
12.87
Volume
2.62M
Market cap
$1.25B
P/E (TTM)
—
52W range
1.50 – 16.33
Day trading desk
Gap from prior close
-0.91%
Prior close 13.15
VWAP
13.19
-0.70% from price
Relative volume
0.53×
Quiet session
Session range
16.46%
12.15 – 14.15
Position in range
47%
Mid range
ATR (14D)
0.77
5.84% of price
Prior day high
13.29
PDH
Prior day low
12.51
PDL
Bid / ask spread
—
Quote not published
Session volume
2.24M
Avg 4.22M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.92%
-0.0%
1M
-11.90%
-13.1%
3M
+19.15%
+14.6%
6M
+69.87%
+51.7%
YTD
+36.32%
+22.1%
1Y
+180.13%
+163.7%
3Y
-22.56%
-104.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on REPL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.54K
Net buying
Buy transactions
4
200.00K shares
Sell transactions
12
184.46K shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
1.55M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 20, 26 | ASTLEY-SPARKE PHILIP Director |
STOCK | 50.00K | $0 | Direct |
| Aug 17, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 9.26K | $132.18K | Direct |
| Aug 10, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 11.45K | $148.48K | Direct |
| Aug 10, 26 | PATEL SUSHIL Chief Executive Officer |
SELL | 39.34K | $510.25K | Direct |
| Aug 10, 26 | XYNOS KONSTANTINOS Officer |
SELL | 11.45K | $148.47K | Direct |
| Aug 10, 26 | SCHWENDENMAN ANDREW Officer |
SELL | 7.63K | $98.99K | Direct |
| Jun 1, 26 | SARCHI CHRISTOPHER Officer |
SELL | 12.00K | $110.88K | Direct |
| May 18, 26 | ASTLEY-SPARKE PHILIP Director |
SELL | 17.66K | $89.70K | Direct |
| May 18, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 7.81K | $39.69K | Direct |
| May 18, 26 | PATEL SUSHIL Chief Executive Officer |
SELL | 37.32K | $189.61K | Direct |
| May 18, 26 | XYNOS KONSTANTINOS Officer |
SELL | 14.02K | $71.24K | Direct |
| May 18, 26 | SCHWENDENMAN ANDREW Officer |
SELL | 7.89K | $40.10K | Direct |
| May 18, 26 | SARCHI CHRISTOPHER Officer |
SELL | 8.63K | $43.82K | Direct |
| Apr 2, 26 | SARCHI CHRISTOPHER Officer |
SELL | 6.50K | $52.06K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASTLEY-SPARKE PHILIP |
Director | 1.36M | Stock Gift |
DHINGRA KAPIL |
Director | 0 | Sale |
HILL EMILY LUISA |
Chief Financial Officer | 215.85K | Sale |
PATEL SUSHIL |
Chief Executive Officer | 708.15K | Sale |
SARCHI CHRISTOPHER |
Officer | 180.96K | Sale |
SCHWENDENMAN ANDREW |
Officer | 99.42K | Sale |
XYNOS KONSTANTINOS |
Officer | 224.22K | Sale |
Fundamentals
Market cap$1.25B
Enterprise value$1.17B
Revenue (TTM)—
Gross profit—
EBITDA$-290.44M
Net income$-297.01M
EPS (TTM)$-3.17
Free cash flow$-171.67M
Total cash$195.33M
Total debt$111.97M
Book value / share$1.26
Shares outstanding94.22M
Float67.65M
Short % of float33.69%
Dividend yield0.00%
Beta (5Y)0.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.29
PEG ratio—
Price / sales—
Price / book10.53
EV / revenue—
EV / EBITDA-4.01
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-134.29%
Return on assets-51.30%
Debt / equity105.99
Current ratio5.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $221.18M | $189.45M | $174.96M | $126.53M | +16.8% |
| Selling, general & admin | $98.73M | $72.18M | $59.81M | $50.55M | +36.8% |
| Total operating expense | $318.31M | $259.85M | $232.85M | $174.17M | +22.5% |
| Operating income | -$318.31M | -$259.85M | -$232.85M | -$174.17M | -22.5% |
| Net interest income | -$8.86M | -$7.89M | -$6.66M | -$4.16M | -12.2% |
| Pre-tax income | -$314.49M | -$246.83M | -$215.39M | -$174.00M | -27.4% |
| Tax provision | -$551.00K | $468.00K | $408.00K | $288.00K | -217.7% |
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M | -26.9% |
| Net income to common | -$313.94M | -$247.30M | -$215.79M | -$174.28M | -26.9% |
| Basic EPS | -3.38 | -3.07 | -3.24 | -2.99 | -10.1% |
| Diluted EPS | -3.38 | -3.07 | -3.24 | -2.99 | -10.1% |
| EBIT | -$305.63M | -$238.94M | -$208.73M | -$169.84M | -27.9% |
| EBITDA | -$302.30M | -$235.43M | -$206.07M | -$167.39M | -28.4% |
| Basic shares | 92.80M | 80.56M | 66.57M | 58.21M | +15.2% |
| Diluted shares | 92.80M | 80.56M | 66.57M | 58.21M | +15.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $209.02M | $111.12M | $74.46M | $146.59M | +88.1% |
| Cash & short-term investments | $268.89M | $483.80M | $420.67M | $583.39M | -44.4% |
| Total current assets | $279.12M | $495.88M | $433.67M | $592.60M | -43.7% |
| Property, plant & equipment | $48.62M | $52.55M | $52.35M | $52.35M | -7.5% |
| Total assets | $332.39M | $551.33M | $487.72M | $646.59M | -39.7% |
| Total current liabilities | $58.23M | $62.36M | $40.44M | $33.83M | -6.6% |
| Long-term debt | $83.31M | $46.38M | $44.81M | $28.65M | +79.6% |
| Total debt | $111.59M | $76.17M | $75.87M | $60.76M | +46.5% |
| Total liabilities | $166.23M | $135.49M | $113.21M | $91.30M | +22.7% |
| Retained earnings | -$1.26B | -$948.58M | -$701.28M | -$485.49M | -33.1% |
| Shareholder equity | $166.16M | $415.84M | $374.51M | $555.29M | -60.0% |
| Working capital | $220.89M | $433.52M | $393.23M | $558.78M | -49.0% |
| Net tangible assets | $166.16M | $415.84M | $374.51M | $555.29M | -60.0% |
| Shares issued | 82.72M | 77.09M | 61.42M | 56.68M | +7.3% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M | -26.9% |
| Depreciation & amortisation | $3.33M | $3.50M | $2.65M | $2.45M | -4.9% |
| Stock-based compensation | $32.27M | $35.04M | $34.13M | $28.13M | -7.9% |
| Change in working capital | -$3.84M | $20.97M | $2.44M | $12.47M | -118.3% |
| Operating cash flow | -$280.34M | -$192.25M | -$185.47M | -$128.05M | -45.8% |
| Capital expenditure | -$4.22M | -$6.69M | -$5.66M | -$2.27M | +36.8% |
| Investing cash flow | $310.84M | -$23.80M | $97.20M | -$142.50M | +1,406.3% |
| Financing cash flow | $66.29M | $252.40M | $16.28M | $311.30M | -73.7% |
| Free cash flow | -$284.57M | -$198.94M | -$191.13M | -$130.32M | -43.0% |
| End cash position | $210.73M | $112.82M | $76.16M | $148.23M | +86.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $49.28M | $52.32M | $53.14M | $57.88M | $57.84M | — | -5.8% |
| Selling, general & admin | $18.97M | $21.01M | $18.73M | $26.41M | $32.58M | — | -9.7% |
| Total operating expense | $67.95M | $72.87M | $71.53M | $83.91M | $90.00M | — | -6.8% |
| Operating income | -$67.95M | -$72.87M | -$71.53M | -$83.91M | -$90.00M | — | +6.8% |
| Net interest income | -$3.09M | -$2.88M | -$1.98M | -$2.01M | -$2.00M | — | -7.3% |
| Pre-tax income | -$69.77M | -$73.46M | -$71.24M | -$83.10M | -$86.69M | — | +5.0% |
| Tax provision | — | -$240.00K | -$311.00K | — | — | -$107.00K | — |
| Net income | -$69.77M | -$73.22M | -$70.93M | -$83.10M | -$86.69M | — | +4.7% |
| Net income to common | -$69.77M | -$73.22M | -$70.93M | -$83.10M | -$86.69M | — | +4.7% |
| Basic EPS | -0.72 | — | -0.77 | -0.90 | -0.95 | — | — |
| Diluted EPS | -0.72 | — | -0.77 | -0.90 | -0.95 | — | — |
| EBIT | -$66.68M | -$70.58M | -$69.26M | -$81.09M | -$84.70M | — | +5.5% |
| EBITDA | -$65.74M | -$69.81M | -$68.41M | -$80.25M | -$83.82M | — | +5.8% |
| Basic shares | 96.86M | — | 92.19M | 91.92M | 91.52M | — | — |
| Diluted shares | 96.86M | — | 92.19M | 91.92M | 91.52M | — | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $185.36M | $209.02M | $122.95M | $102.30M | $97.37M | -11.3% |
| Cash & short-term investments | $195.33M | $268.89M | $269.14M | $323.64M | $403.34M | -27.4% |
| Total current assets | $200.81M | $279.12M | $280.35M | $333.75M | $413.37M | -28.1% |
| Property, plant & equipment | $46.70M | $48.62M | $50.33M | $52.00M | $52.80M | -4.0% |
| Total assets | $252.45M | $332.39M | $333.59M | $389.45M | $469.51M | -24.1% |
| Total current liabilities | $38.41M | $58.23M | $50.09M | $52.90M | $59.56M | -34.0% |
| Long-term debt | $84.11M | $83.31M | $47.63M | $47.21M | $46.79M | +1.0% |
| Total debt | $111.97M | $111.59M | $76.35M | $76.32M | $76.33M | +0.3% |
| Total liabilities | $146.80M | $166.23M | $123.05M | $126.11M | $132.79M | -11.7% |
| Retained earnings | -$1.33B | -$1.26B | -$1.19B | -$1.12B | -$1.04B | -5.5% |
| Shareholder equity | $105.64M | $166.16M | $210.54M | $263.34M | $336.71M | -36.4% |
| Working capital | $162.40M | $220.89M | $230.27M | $280.85M | $353.81M | -26.5% |
| Net tangible assets | $105.64M | $166.16M | $210.54M | $263.34M | $336.71M | -36.4% |
| Shares issued | 83.98M | 82.72M | 79.63M | 78.40M | 77.81M | +1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$69.77M | -$73.22M | -$70.93M | -$83.10M | -$86.69M | +4.7% |
| Depreciation & amortisation | $937.00K | $769.00K | $848.00K | $842.00K | $873.00K | +21.8% |
| Stock-based compensation | $7.67M | $8.13M | $7.05M | $8.34M | $8.76M | -5.6% |
| Change in working capital | -$15.50M | $6.88M | -$3.43M | -$6.87M | -$417.00K | -325.4% |
| Operating cash flow | -$75.73M | -$56.16M | -$65.95M | -$81.21M | -$77.02M | -34.8% |
| Capital expenditure | -$6.00K | -$5.00K | -$135.00K | -$1.34M | -$2.74M | -20.0% |
| Investing cash flow | $49.99M | $86.51M | $75.12M | $84.17M | $65.05M | -42.2% |
| Financing cash flow | $800.00K | $55.68M | $10.45M | $324.00K | -$158.00K | -98.6% |
| Free cash flow | -$75.73M | -$56.17M | -$66.09M | -$82.56M | -$79.76M | -34.8% |
| End cash position | $187.06M | $210.73M | $124.66M | $104.00M | $99.08M | -11.2% |
Options analytics
Put / call volume
2.63
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-62.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
38
Contracts, this expiry
Put volume
100
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
10.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -0.72 | +6.3% |
| Mar 2026 | -0.72 | -0.76 | -5.6% |
| Dec 2025 | -0.82 | -0.77 | +6.5% |
| Sep 2025 | -0.79 | -0.90 | -13.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.79 | 2 | $0 | 0.0% |
| Next quarter | -0.76 | 2 | $6.69M | 0.0% |
| Current year | -3.01 | 2 | $28.87M | 0.0% |
| Next year | -1.82 | 3 | $172.57M | +497.8% |
Analyst targets & ownership
Mean target$19.50
High target$24.00
Low target$14.00
Implied upside48.85%
Analyst count6
ConsensusBUY
Strong buy / Buy2 / 5
Hold0
Sell / Strong sell1 / 0
Held by insiders1.65%
Held by institutions105.77%
Institutions holding254
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.96
+1.05% from price
SMA 20
13.08
+1.29% from price
SMA 50
13.31
-0.48% from price
SMA 100
11.21
+16.86% from price
SMA 200
8.95
+48.12% from price
EMA 12
13.15
-0.37% from price
EMA 26
13.30
-1.51% from price
EMA 50
12.89
+1.63% from price
RSI (14)
49.4
Neutral
MACD (12,26,9)
-0.15
Hist 0.01
ATR (14)
0.77
5.77% of price
Realised vol 30D
46.7%
Annualised
Bollinger upper
13.91
20, 2σ
Bollinger lower
12.25
20, 2σ
50 / 200 cross
Golden
13.31 vs 8.95
Trend bias
Above 200
+48.12%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.48
More volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
46.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-84.2%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
0.77
5.77% of price
Beta (reported)
0.94
5Y monthly, from filing
Short interest
Shares short
22.75M
Prior 24.87M
Change vs prior
-8.5%
Shorts covering
% of float
33.69%
Heavily shorted
% of shares out
24.15%
Against total outstanding
Days to cover
9.4
Crowded exit
Float
67.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 26, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Wedbush | UPGRADE | Neutral | Outperform |
| Aug 4, 26 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Jul 31, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jul 31, 26 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
| Jun 30, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jun 26, 26 | JP Morgan | UPGRADE | Neutral | Overweight |
| Jun 1, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| May 29, 26 | JP Morgan | UPGRADE | Underweight | Neutral |
| Apr 13, 26 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Apr 13, 26 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Offering Registrations
S-3ASR · 2026-08-14
Corporate Changes & Voting Matters
8-K/A · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-30
Proxy Statements
DEF 14A · 2026-07-29
Headlines
Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
MT Newswires · 5d ago
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
GlobeNewswire · 5d ago
Trump Administration Shift Puts This Corner of Biotech Back in Favor
The Wall Street Journal · 21d ago
Replimune to Present at the Cantor Global Healthcare Conference 2026
GlobeNewswire · 34d ago
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Stocktwits · 41d ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 48d ago
Replimune Fiscal Q1 Net Loss Narrows
MT Newswires · 54d ago
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
GlobeNewswire · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.